Development of a plant-made pharmaceutical production platform

BioProcess International

Volumn 10, Issue 1, 2012, Pages

  Everett, Keith M ^a   Dickey, Lynn ^a   Parsons, John ^a   Loranger, Rachel ^a   Wingate, Vincent ^a  

^a Biolex Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA INTERFERON; APOLIPOPROTEIN A1; BIOSIMILAR AGENT; GLUCOSYLCERAMIDASE; INFLUENZA VACCINE; INSULIN; MONOCLONAL ANTIBODY; VACCINE;

ASEPSIS; CARDIOVASCULAR DISEASE; CELL CULTURE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG INDUSTRY; DRUG MANUFACTURE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GAUCHER DISEASE; HEPATITIS B; HEPATITIS C; INFLUENZA A (H1N1); INFLUENZA A (H5N1); NEOPLASM; NEWCASTLE DISEASE; PHARMACEUTICAL ENGINEERING; PHARMACEUTICS; PLANT MADE PHARMACEUTICAL; PRACTICE GUIDELINE; PROCESS CONTROL; PRODUCTIVITY; REVIEW;

EID: 84855827871     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (11)

1. Office of the Press Secretary, The White House. Fact Sheet: Obama Administration Takes Action to Reduce Prescription Drug Shortages in the US; 31 October 2011; www.whitehouse.gov/the-press-office/2011/10/31/fact-sheet-obama- administration-takes-action-reduce-prescription-drug-sh.
2. Molecular Farming: Plant Bioreactors. Bio Pro, Baden-Württemberg; www.bio-pro.de/magazin/thema/00178/index.html?lang=en.
3. Thomson JA. Seeds for the Future: The Impact of Genetically Modified Crops on the Environment. Cornell University Press, Ithaca, NY; 2006.
4. Gasdaska JR, Spencer D, Dickey L. Advantages of Therapeutic Protein Production in the Aquatic Plant Lemna. BioProcessing J March-April 2003: 49-56.
5. Cox KM, et al. Glycan Optimization of a Human Monoclonal Antibody in the Aquatic Plant Lemna minor. Nature Biotech. 24 2006: 1591-1597. (Pubitemid 44967485)
6. Dzublyk I, et al. Phase 2a Study to Evaluate the Safety and Tolerability and Antiviral Effect of Four Doses of a Novel, Controlled-Release Interferon alfa-2b (Locteron™) Given Every Two Weeks for 12 Weeks in Treatment-Naïve Patients with Chronic Hepatitis C (Genotype 1). J. Hepatology 46, 2007: 4S:232A.
7. Lawitz E, et al. Early Viral Response of Controlled-Release Interferon alpha2b and Ribavirin vs. Pegylated Interferon alpha 2b and Ribavirin in Treatment-Naïve Genotype1 Hepatitis C: 12 Week Results (SELECT-2 Trial). J. Hepatology 52, 2010: S114.
8. Long WA, et al. Timing and Frequency of Depression During HCV-Treatment with Controlled Release INFa2b (CR2b) vs. Pegylated IFNa2b (PEG2b): Results from SELECT-2, a Randomized Open-Label 72-Week Comparison in 116 Treatment-Naïve Patients with Genotype 1 HCV. J. Hepatology 54, 2011: S181-182.
9. Cox KM. Production of Antibodies in Plants. An Z and Strohl W, Eds. Therapeutic Antibodies: From Theory to Practice. Wiley, Inc: New York, NY; September 2009.
10. Private communication between Biolex and regulatory authorities
11. Biolex internal documents.